6 days after tumour challenge. There was then a rapid increase in primary tumour size, especially over the 7-14-day interval, with a plateau of growth over the 18-21 -day interval. Immunoreactive plasma fibronectin was significantly (P<0.05) raised at 3 and 7 days after tumour challenge. A rapid rise (P < 0-001) to 2816.6 + 158*9 ,ug/ml was observed at 14 days followed by a modest decline at 21 days. Bioassayable opsonic activity increased (P <0.05) with the rise in immunoreactive fibronectin 3 and 7 days after tumour challenge, but the rapid rise in immunoreactive fibronectin over the 7-14-day interval was associated with a significant (P<0.05) fall in bioassayable opsonic activity. Thus, the rapid rise in immunoreactive plasma fibronectin parallels the rapid rate of tumour growth, but is associated with a fall in opsonically active plasma fibronectin. Dissociation between immunoreactive and opsonically active plasma fibronectin may be mediated by inhibition and/or alteration of circulating fibronectin during rapid tumour growth. Alternatively, it may reflect increased release of antigenically related protein (i.e. cell-surface fibronectin) during rapid tumour growth, which may have limited biological opsonic activity.
MACROPHAGES may represent a primitive and effective cellular anti-tumour surveillance mechanism (Diller et al., 1963; Di Luzio, 1975; Hibbs et al., 1972a,b; Levy & Wheelock, 1974; Old et al., 1960; Stern, 1960) . Stimulation of the macrophage system increases resistance to tumour challenge (Diller et al., 1963; Stern, 1960) and macrophage depression decreases resistance to tumour growth. Moreover, RES phagocytic activity in various strains of inbred mice correlates with their spontaneous incidence of malignant disease (Stern, 1960) .
The reticuloendothelial response to tumour growth is typically early activation followed by progressive decline in RES function as measured by the clearance of gelatin-coated test colloids (Old et al., 1960 (Old et al., , 1961 Saba & Antikatzides, 1975) . The importance of opsonic a2
surface-binding (SB) glycoprotein in mediating RE-cell clearance of gelatinized test colloids has been documented (Blumenstock et al., 1977a; Saba, 1970; Saba et al., 1978a,b) . Determinations of opsonic a2SB glycoprotein levels by the standard liverslice bioassay have demonstrated a decline following colloid-induced RE blockade (Saba & Di Luzio, 1969) as well as after major surgery, burn injury and traumatic shock (Saba, 1970 (Saba, , 1972 1978a,b; Scovill et al., 1978) . Circulating bioassayable opsonic activity in animals during tumour growth (Saba & Antikatzides, 1975 Saba & Cho, 1977) directly correlates with phagocytic activity as evaluated by colloid clearance. Somewhat analogous clinical studies by Pisano et al. (1972) as well as Di Luzio (1975) with the bioassay have demonstrated deficiency in bioassayable opsonic activity in patients with advanced malignant disease.
Isolation and characterization of opsonic A2SB glycoprotein had led to our discovery that cold-insoluble globulin (CIg) or plasma fibronectin is identical to opsonic protein Blumenstock et al., 1978b) . Moreover, opsonic protein or plasma fibronectin can now be quantified by electroimmunoassay in animals (Saba, 1978) and humans . Since deficiency of opsonic activity as measured by bioassay during tumour growth could reflect inhibition of the biological activity of plasma fibronectin and/or modification of the circulating molecule, as opposed to consumptive depletion from the blood as seen after surgery or trauma (Saba et al., 1978a,b) we compared levels of circulating immunoreactive plasma fibronectin as well as bioassayable opsonic plasma fibronectin (CIg) during tumour growth.
MATERIALS AND METHOI)S Tumour transplantation. Male C57BL/6 mice weighing 20-25 g were recipients of the S-180 tumour for both serial transplantation and individual experiments. Serial transplantation was done every 18-21 days. The Sarcoma-180 tumour (S-180) in mice was used since it is a rapidly growing tumour which can be readily quantified, and which produces significant changes in RES phagocytic clearance (i.e. early activation followed by progressive RES decline). The tumour was excised from the leg under sterile conditions under ether anaesthesia using a UV transplantation box. The viable periphery of the tumour was passed through a sterile 170,um-pore microsieve. Tumour cells were collected in sterile saline, wxNashed twice and recovered in sterile saline after cenitrifugation at 1500 rev/min for 10 min at 4°C. Cell concentration wvas determined by haemacytometric methods, and cell viability by trypanblue exclusion. For both serial transplantation and experimental studies, recipient mice received s.c. (right leg) 2 x 106 viable S-180 tumour cells in 0-2 ml of sterile saline. Controls were injected s.c. with 0-2 ml of sterile saline.
Grozwth curve of tumour. Periodically after transplantation, the primary tumour size was determined by calipers (Saba & Antikatzides, 1975) . Three orthagonal diameters were used for the calculation of tumour volume and tumour weight as originally described (Schrek, 1935) . Tumour volume in cm3 was estimated 0-5236d3 where d is the mean tumour diameter as quantified from 3-dimension measurements. Tumour weight (g) was then estimated as 1-038 x 0-5236d3, where the constant 1 038 is used as the specific gravity of the tumour. These determinations correlate very wvell with actual tumour weight after careful surgical removal (Saba & Cho, 1977) .
Bioassay of opson,ic activity. Mouse plasma was obtained after decapitation from both control and tumour-bearing C57BL/6 mice. Blood was collected in plastic centrifuge tubes supplemented with heparin (100 USP u/ml) and immediately centrifuged at 5000 rev/min for 20 min at 4°C to collect plasma. Heparin is the anticoagulant to use in the liver-slice bioassay of plasma opsonic activity, since its presence is a prerequisite for maximal expression of biological activity (extensively documented by Saba, 1970; Saba et at., 1966) and EDTA, citrate or oxalate block the assay (Ryder et al., 1975) . Heparin will, however, alter the assay if the plasma is stored at 4°C for extended periods before biological assay, since it will complex fibronectin and increase its cryoprecipitation from the plasma. Plasma opsonic activity was determined by the standard in vitro liver-slice bioassay (Blumenstock et at., 1977b; DiLuzio et al., 1972; Pisano et al., 1972; Saba, 1972 Saba, , 1978 . The 3.0 ml test medium consisted of KrebsRinger phosphate (pH 7 4), 100 USP u heparin (Upjohn, Kalamazoo. MI), and the gelatinized 1311-labelled "RE test lipid emulsion", as previously described (Saba, 1972; Saba & Antikatzides, 1975) . Normal or experimental plasma for analysis was added to the incubation flask at a concentration of 25% (0 75 ml plasma and 2-25 ml buffer). Each incubation flask, containing a 200-300mg liver slice, was supplemented with 2-0 mg of the test gelatinized particles and incubation was conducted with oscillation for 30 min under a gas phase of 95% 02 and 5%
CO2 at 37°C in a Dubnoff metabolic shaker. After incubation, liver-slice uptake of the test particles was determined by isotopic assay. Phagocytic uptake was expressed as the percentage of added colloid dose (%ID) phagocytosed per 100 mg liver slice. This method has been previously used in various experimental and clinical studies Di Luzio, 1975; Saba & Antikatzides, 1975; Saba et al., 1978a,b) . Additionally, the use of the gelatinized "RE test lipid emulsion", as opposed to inert particles such as gelatincoated colloidal gold or gelatinized latex spheres, produces a higher degree of hepatic Kupffer-cell ingestion of the test particles (Hopps & Szakacs, 1967) as opposed to a high degree of external binding to Kupffer cells. The correlation between the bioassay and the immunoassay has been documented in normal states and after trauma, surgery and RE blockade (Blumenstock et al., 1977b; Saba, 1978; Saba et al., 1978a,b; Scovill et al., 1978) .
The 1311 radioactivity was determined with a Nuclear-Chicago auto gamma crystal scintillation system equipped with a 2-inch thallium-activated sodium iodide crystal. All samples were counted in duplicate with independent isotope standards in each experiment.
Purification of mouse opsonin by affinity chromatography.-Blood from donor mice was collected in 50ml plastic centrifuge tubes and allowed to clot for 1 h at room temperature. Serum was collected by centrifugation at 5000 rev/min for 20 min at 4C, and recentrifuged at 10,000 rev/min for 20 min at 4W. The isolation procedure used a gelatinSepharose column as previously described to purifv fibronectin (Engvall & Ruoslahti, 1977) but with modification and inclusion of mercaptoethanol (Blumenstock et al., 1979) to help preserve biological activity as revealed by our previous studies (Blumenstock et at., 1978a,b) . There is a biospecific absorption of the opsonic protein (cold-insoluble globulin; plasma fibronectin) to gelatin (denatured collagen) which appears unique to this plasma protein. The details of the affinity purification procedure to obtain biologically active and purified animal and human opsonic protein has been recently described in detail (Blumenstock et al., 1979; Saba & Cho, 1979) .
The plasma fibronectin protein (opsonin) isolated from mice has a high affinity for gelatin (denatured collagen), will stimulate macrophage phagocytosis, and has a molecular structure similar to that of rat and human plasma fibronectin, as tested by gradient gel electrophoresis.
Antiserum preparation.-Antiserum to the isolated opsonic 0x2SB glycoprotein or plasma fibronectin was prepared in rabbits as previously described (Blumenstock et al., 1977b ). An immunoabsorbent consisting of glutaraldehyde-cross-linking opsonin-deficient serum can be used for preparation of monospecific antiserum as previously documented (Blumenstock et al., 1977b) . However, with affinity chromatography for antigen isolation, the antiserum developed is often monospecific, as verified by immunoelectrophoresis, which is similar to the results with human protein (Blumenstock et al., 1979; Saba et al., 1978b ).
Quantification of immunoreactive fibronectin
(opsonic cX2SB glycoprotein).-Electroimmunoassay or "rocket" immunoelectrophoresis was used to measure plasma fibronectin or opsonic protein levels, as previously described (Blumenstock et al., 1977b; Saba & Cho, 1979; Saba et al., 1978a) . Experimental serum was assayed for immunoreactive fibronectin. It was collected via the tail vein under light ether anaesthesia. Blood samples were allowed to clot for 60 min at 25WC before centrifugation to obtain serum. It is recognized that the serum concentration of circulating fibronectin (opsonic glycoprotein) is consistently less than that of plasma, due to the incorporation or covalent binding of plasma fibronectin to fibrin in the presence of Factor XIII (Mosher, 1976) . This difference is minimal if the blood is allowed to clot at room temperature before collection of the serum (Mosesson, 1972) . All samples for analysis were carefully handled under such constant conditions so that serum could be the test medium used for the immunoassay, as previously standardized (Blumenstock et al., 1977b) . The serum was diluted to 10% and 10 ,ul was added to each well cut into the solidified agarose-antiserum solution layer on the glass plate (5 x 10 inch) used in the electroimmunoassay as described (Blumenstock et al., 1977b) . The samples were then moved electrophoretically towards the anode at a voltage of 7-5 V/cm at 4°C for 22 h using an LKB multiphore system (Blumenstock et al., 1977b) . The plates were washed overnight, pressed and dried, and subsequently stained (Blumenstock et al., 1977b) . Rocket heights were used as a quantitative index of immunoreactive opsonic CX2SB glycoprotein concentration. Rocket heights were recorded in millimeters, and a double-reciprocal standard plot (1/mm vs l/ug opsonic or 1/mm v8 1% serum) was defined with a DEC-10 computer using protein standards at varying concentrations. This standard curve was used to determine serum immunoreactive opsonic O2SB glycoprotein in ,tg/ml . Fig. 1 plasma and uptake of the gelatinized "RE test lipid emulsion" in the liver-slice bioassay. Uptake was minimal in the artificial Krebs-Ringer phosphate buffer in the absence of plasma. In contrast, with increasing concentration of plasma, there was a significant (P < 0-0f5) increase in uptake of the gelatinized 1311 RE test lipid emulsion with an apparent plateau beginning at a plasma concentration of about 66%. The linear portion of the sensitivity curve for the bioassay with mouse plasma was -0 75 ml, which corresponded to a plasma concentration of 25%. Plasma fibronectin concentration in such normal mouse plasma is typically 1050-1150 ,ug/ml. It has already been documented (Blumenstock et al., 1979 Saba & Cho, 1979 ) that the active factor in plasma responsible for the bioassay response is the opsonic a2SB glycoprotein (plasma fibronectin; CJg). Indeed, plasma made specifically deficient in plasma fibronectin by passing via the affinity column is incapable of stimulating the liver-slice bioassay (Blumenstock et al., 1979; Saba & Cho, 1979) and its activity can be recovered by reconstitution with the purified protein (Saba & Cho, 1979) . On the basis of these data, 0-75ml plasma aliquots obtained at varying intervals during the course of S-180 tumour growth was assayed for its opsonic activity in this bioassay. Fig. 2 documents the monospecific nature of the rabbit antiserum to the mouse plasma fibronectin, as verified by immunoelectrophoresis of the antiserum against normal mouse serum and affinitypurified mouse opsonic protein (plasma fibronectin) used to immunize the rabbits. Single precipitin arcs are evident with either substrate, confirming the monospecificity of the antiserum. Fig. 3 is a composite presentation of the temporal pattern of immunoreactive opsonin (fibronectin), bioassayable opsonic activity and primary tumour growth as a function of time after tumour challenge. In this particular study, 120 [g/ml) . Thereafter, an increase (P<0 001) to a maximum of 2816*6+ 158-9 jug/ml by 14 days was seen in parallel with increased tumour size (Fig.  3 ). This level is higher than we have ever observed in normal rats, rabbits, sheep and man, although patients with lung cancer do have very high immunoreactive plasma fibronectin levels (Saba & Blumenstock, unpublished) . Then there is a significant (P < 0.05) decline in immunoreactive protein by 21 days, but this level 1922*9 + 85 7 Hg/ml) is still above control. The trend for immunoreactive protein to begin to decrease by 21 days is temporally correlated with stabilization of the bioassayable level, but the significance of this pattern remains to be determined. These new findings reflect a clear disparity between the immunoreactive circulating opsonin (fibronectin) level and the bioassayable circulating opsonin (fibronectin) level during rapid tumour growth, as clearly summarized in Fig. 4 , which presents these 2 parameters at the 7-and 14-day interval of rapid tumour growth.
RESULTS

Presented in
DISCUSSION
Reticuloendothelial (RE) cells rapidly phagocytose foreign particles, denatured protein, tumour cells and effete autologous tissue debris (Bennett et al., 1964; Chamber & Weiser, 1973; Di Luzio, 1975; Saba, 1970 (Biozzi et al., 1958; Diller et al., 1963; Saba, 1970) .
Macrophage discrimination between foreign matter (non-self), altered endogenous tissue (altered self) and healthy indigenous tissue (self) (Saba, 1970) (Di Luzio, 1975; Pisano et al., 1972; Saba, 1970 (Biozzi et al., 1958; Di Luzio et al., 1974; Hibbs et al., 1972a,b; Keller, 1975; Keller & Hess, 1972; Old et al., 1961 Additionally, phagocytosis is greatest in inbred mice manifesting the lowest incidence of spontaneous tumours, whilst mice with the greatest incidence of spontaneous tumours have lower basal levels of RE activity (Stern et al., 1967; Stern, 1960) .
In the Walker-256 tumour model, phasic alterations of RES phagocytic capacity are correlated with bioassayable plasma opsonic activity (Saba & Antikatzides, 1975 ). An early rise in plasma opsonin activity correlates with hyperphagocytosis, whilst later opsonic deficiency correlates with RES dysfunction. Pisano et al. (1972) have also demonstrated bioassayable opsonic deficiency in patients with advanced carcinoma. At the time of our previous studies, the immunoassay for opsonic protein was not available, so it was not possible to determine whether bioassayable opsonic deficiency was due to depletion of plasma protein from the circulation or inhibition of its biological activity in the plasma. The fact that circulating gelatin-coated particles (Blumenstock et al., 1977b) or viable tumour cells such as leukaemic leucocytes will readily decrease opsonic activity as well as the observation that purified 1251 opsonic protein in the blood is sequestered into a site of tissue injury, suggested a depletion deficiency. However, the possibility that the tumour may depress opsonic activity was apparent in view of the rapid recovery of bioassayable opsonic activity in cancer patients after surgical removal of their tumour (Di Luzio, 1975; Pisano et al., 1972) .
The concept of increased tumour immunity after nonspecific macrophage activation has been emphasized (Hibbs et al., 1972b; Keller, 1975 Keller, , 1976 . Macrophage activation has been correlated with suppression of tumour growth (Keller, 1975; Keller & Hess, 1972) and may reflect an increased participation of macrophages in the rejection process via a nonspecific or specific process (Di Luzio, 1975; Keller, 1975; Levy & Wheelock, 1974 Keller, 1975; Levy & Wheelock, 1974) . Macrophages can induce lvsis of tumour cells, and such lytic ability appears to be related to contactinduced destruction and associated release of lysosomal enzymes (Hibbs, 1974; Journey & Amos, 1962; Keller, 1973; Keller & Hess, 1972) . Thus, the antitumour immunity expressed by macrophages may be related to recognition of abnormal cells and phagocytic destruction, as well as to extracellular cytotoxic and cytostatic mechanisms (Bennett et al., 1964; Keller, 1975) .
Biochemical characterization Blumenstock et al., 1978b) of opsonic A2SB glycoprotein has led to our discovery that cold-insoluble globulin (Mosesson, 1972 ) also called plasma fibronectin (Yamada & Olden, 1978 ) is identical to opsonic protein. Plasma fibronectin is antigenically related to an adhesive-cellassociated glycoprotein known as cellsurface fibronectin, large external transformation sensitive (LETS) protein (Hynes et al., 1978) , fibroblast surface antigen (Rouslahti & Vaheri, 1975) and cellattachment factor (Yamada & Olden, 1978) . Cell-surface fibronectin is found on vascular endothelial cells (Jaffe & Mosher, 1978) as well as fibroblasts in tissue culture (Rouslahti & Vaheri, 1975) . We have also shown it on the surface of macrophages, and RE cells may be a major site of opsonic protein production, as originally speculated (Saba, 1970 ). It appears essential for adherence of fibroblasts to a collagenous substrate and is lost from the cell surface after oncogenic transformation (Hynes et al., 1978; Yamada & Olden, 1978) . Such loss is associated with altered cell adhesion, morphology and cell interaction (Yamada & Olden, 1978) . This suggests that altered cell-surface fibronectin might lead to decreased attachment and increased metastatic potential. However, others such as Der & Stanbridge (1978) suggest that there is no correlation between decreased expression of cellsurface LETS protein and increased tumorigenicity of specific cell lines. Yamada & Kennedy (1979) have shown that fibroblast cellular fibronectin and plasma fibronectin are very similar but may not be identical. While the plasma form is active in stimulating phagocytosis (Blumenstock et al., 1979; Saba & Cho, 1979) it has yet to be proved whether or not the cell-surface protein in its native form and configuration has such biological activity. Cell-surface fibronectin may primarily participate as an adhesive glycoprotein, while the more soluble plasma and lymph fibronectin may participate as an opsonic molecule in augmenting macrophage host-defence mechanisms (Saba & Jaffe, 1980 ). Injured septicpatients demonstrate immunoreactive and bioassayable opsonic fibronectin deficiency correlated with failure of host defence and organs (Saba et al., 1978a,b; Scovill et al., 1978) . Infusion of cryoprecipitate which is rich in opsonic ac2SB glycoprotein will reverse opsonic deficiency in such patients (Saba et al., 1978a,b; Scovill et al., 1978) with marked improvement in cardiovascular, pulmonary and host defence function.
In the present study, the separation of immunoreactive and bioreactive fibronectin with rapid tumour growth may be of importance to macrophage anti-tumour defence mechanisms during cancer. Before the immunoassay became available, it was assumed that deficiency of opsonic activity during advanced cancer represented depletion as observed after RE blockade (Blumenstock et al., 1977a; Saba & Di Luzio, 1969) or surgery and trauma (Saba et al., 1978a,b; Scovill et at., 1978) . Confirmation of depletion after blockade (Blumenstock et al., 1977b) or trauma (Saba & Cho, 1979; Saba et al., 1978b) has been obtained by immunoassay, but the present data suggest an alternate mechanism during cancer. Tumour growth and spread may produce either inhibition and/ or proteolytic destruction of biologically active plasma fibronectin, resulting in immunoreactive fragments without biological activity.
Fibronectin may be bound in the plasma to circulating entities and thus detectable by immunoassay but undetectable by bioassay. An alternate explanation may be related to the antigenic similarities, but potentially subtle functional differences between cell-surface fibronectin and plasma fibronectin (Saba & Jaffe, 1980) . Thus the great increase in immunoreactive protein may reflect abnormal release of cellsurface fibronectin (or fragments of molecule) which are antigenically related, but not as active for stimulating phagocytosis. Such fragments may also competitively inhibit the bioassay. The release of LETS with malignant transformation (Hynes et al., 1978) the antigenic crossreactivity of cell-surface and plasma fibronectin (Yamada & Olden, 1978; Ruoslahti & Vaheri, 1975) and the subtle differences between the cell-surface and the plasma form of the protein (Yamada & Kennedy, 1979) all indirectly support this concept.
Whilst the basis for the "blunting" of the bioassayable opsonic activity during tumour growth and spread can only be speculated on, this may compromise macrophage anti-tumour defence activity. Moreover, the possibility that an acute rise in immunoreactive non-opsonically active fibronectin may indirectly serve as a marker for rapid tumour growth warrants investigation.
